Study #2018-0875
A Phase II Study of Open Label Low Dose Ipilimumab in Combination with Pembrolizumab in Metastatic Melanoma Patients with Brain Metastases
MD Anderson Study Status
Not Accepting
Treatment Agent
Ipilimumab, Pembrolizumab
Description
This phase II trial studies the side effects and how well low dose ipilimumab works in combination with pembrolizumab in treating patients with melanoma that has spread to the brain. Immunotherapy with monoclonal antibodies, such as ipilimumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Clinical Stage IV Cutaneous Melanoma AJCC V8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC V8
Study phase:
Phase II
Physician name:
Isabella Glitza Oliva
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-866-253-6411
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.